{"entity":{"id":"paper-katsin-by19-cd19-car-t-belarus-mol-ther-oncol-2025","kind":"paper","name":"BY19: a CD19 CAR T-cell therapy made in Belarus, phase 1 trial","aka":[],"tldr":"In a single-arm early trial at two Belarusian centres, a CD19 CAR T-cell product made in Belarus treated 23 children and adults with relapsed B-cell cancers; 16 of 20 who could be assessed responded.","summary":"Published as \"CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial\". A single-arm, open-label phase 1 trial (NCT05333302) of an in-house manufactured CD19 CAR T-cell product, BY19, after lymphodepletion with fludarabine and cyclophosphamide, with or without decitabine. Authors are from the Vitebsk Regional Clinical Cancer Centre, the Institute of Bioorganic Chemistry of the National Academy of Sciences and the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology.","asOf":"2026-11-11","links":[{"label":"Mol Ther Oncol 2025","url":"https://doi.org/10.1016/j.omton.2025.201081"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41322200/"},{"label":"ClinicalTrials.gov: NCT05333302","url":"https://clinicaltrials.gov/study/NCT05333302"}],"tags":[],"related":[],"cancers":["all-leukemia","cll"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["belarus-paediatric-oncology-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Molecular Therapy Oncology","year":2025,"doi":"10.1016/j.omton.2025.201081","pmid":"41322200","authors":"Katsin M, Dormeshkin D, Migas A, et al.","paperType":"translational","findings":["23 patients were treated: 17 with B-cell acute lymphoblastic leukaemia, 1 with chronic lymphocytic leukaemia and 5 with non-Hodgkin lymphoma.","Overall response was 80% (16 of 20 evaluable) and complete remission at day 28 was 75%; median progression-free survival was 23 months.","Cytokine release syndrome occurred in 67% of infusions (severe in 19%) and neurotoxicity in 44% (severe in 18.5%)."],"whatItMeans":"Making CAR T cells locally can bring this treatment to patients in middle-income countries where commercial products are out of reach, with safety and efficacy the authors judge comparable to approved products.","caveats":["Phase 1, single arm, small numbers.","Not compared directly with commercial products."],"participants":23},"route":"/key-papers/paper-katsin-by19-cd19-car-t-belarus-mol-ther-oncol-2025/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"institution":[{"id":"belarus-paediatric-oncology-centre","kind":"institution","name":"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology","route":"/institutions/belarus-paediatric-oncology-centre/"}]}}